ARTICLE | Finance
Form 10 for ADMA
Plasma therapeutics play ADMA raises $17.6M, reverse-merges for Form 10 listing
February 20, 2012 8:00 AM UTC
Investors in ADMA Biologics Inc.'s private placement don't mind holding a relatively illiquid stock, as the syndicate is expecting a Phase III data event before the company's cash runs out in 3Q13.
Last week, the company took its first steps down the Form 10 pathway by reverse-merging with a public shell company and raising $17.6 million through the sale of 1.8 million shares at $9.60. ADMA plans to list on the OTCBB exchange...